These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1871805)

  • 1. Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy.
    Ghany AM; Tutschka PJ; McGhee RB; Avalos BR; Cunningham I; Kapoor N; Copelan EA
    Transplantation; 1991 Aug; 52(2):310-5. PubMed ID: 1871805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
    Kalaycioglu ME; Bolwell BJ
    Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
    Schultz KR; Ratanatharathorn V; Abella E; Eisenbrey AB; Karanes C; Lum LG; de Planque MM; Uberti JP; Ravindranath Y; Sensenbrenner LL
    Bone Marrow Transplant; 1994 Jun; 13(6):817-22. PubMed ID: 7920320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative trial of posttransplant immunosuppression in patients transplanted for thalassemia. Cyclosporine alone versus cyclosporine, cyclophosphamide, and methotrexate.
    Galimberti M; Polchi P; Lucarelli G; Giardini C; Baronciani D; Angelucci E; Politi P
    Transplantation; 1988 Mar; 45(3):566-9. PubMed ID: 3279581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
    Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
    J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation.
    Zimmer WE; Hourihane JM; Wang HZ; Schriber JR
    AJNR Am J Neuroradiol; 1998 Apr; 19(4):601-8; discussion 609-10. PubMed ID: 9576643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
    Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin.
    Reece DE; Frei-Lahr DA; Shepherd JD; Dorovini-Zis K; Gascoyne RD; Graeb DA; Spinelli JJ; Barnett MJ; Klingemann HG; Herzig GP
    Bone Marrow Transplant; 1991 Nov; 8(5):393-401. PubMed ID: 1768975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous busulfan effect in patients receiving bone-marrow transplantation.
    Hymes SR; Simonton SC; Farmer ER; Beschorner WB; Tutschka PJ; Santos GW
    J Cutan Pathol; 1985 Apr; 12(2):125-9. PubMed ID: 3889081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.
    Nagler A; Savani BN; Labopin M; Polge E; Passweg J; Finke J; Kyrcz-Krzemien S; Volin L; Anagnostopoulos A; Aljurf M; Beelen DW; Vigouroux S; Milpied N; Suarez F; Mohty M
    Lancet Haematol; 2015 Sep; 2(9):e384-92. PubMed ID: 26685771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
    Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: role of continuous bladder irrigation.
    Turkeri LN; Lum LG; Uberti JP; Abella E; Momin F; Karanes C; Sensenbrenner LL; Haas GP
    J Urol; 1995 Mar; 153(3 Pt 1):637-40. PubMed ID: 7861502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.